Title:
上皮膜タンパク質2(EMP2)結合試薬および眼疾患治療におけるその使用
Document Type and Number:
Japanese Patent JP2013520446
Kind Code:
A
Abstract:
A method is disclosed for treating diseases or disorders of the eye involving undesired expression of vascular endothelial growth factor (VEGF) by administration of endothelial membrane protein 2 (EMP2) inhibitor. The present invention relates to the direct treatment of macular degeneration, particularly age-related macular degeneration (AMD), by administering an EMP2 inhibitor intraocularly or systemically.
Inventors:
Gordon, Lin Kay.
Brown, jonathan
Morales, Shawn
Terrander, David, Gee.
Wadera, Maduri
Brown, jonathan
Morales, Shawn
Terrander, David, Gee.
Wadera, Maduri
Application Number:
JP2012554099A
Publication Date:
June 06, 2013
Filing Date:
February 22, 2011
Export Citation:
Assignee:
The Regents of The University of California
United States Government Department of Veterans Affairs
United States Government Department of Veterans Affairs
International Classes:
A61K45/00; A61K31/713; A61K39/395; A61K48/00; A61P27/02; C07K16/28; C12N15/113
Domestic Patent References:
| JP2009531463A | 2009-09-03 | |||
| JP2013511543A | 2013-04-04 |
Foreign References:
| WO2009048980A2 | 2009-04-16 |
Other References:
JPN6015007012; Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｏｐｈｔｈａｌｍｏｌｏｇｙ ａｎｄ Ｖｉｓｕａｌ Ｓｃｉｅｎｃｅ Ｖｏｌ．４６, 2005, Ｅ-Ａｂｓｔｒａｃｔ ５０７４
JPN6015007003; Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｏｐｈｔａｌｍｏｌｏｇｙ ａｎｄ Ｖｉｓｕａｌ Ｓｃｉｅｎｃｅ Ｖｏｌ．５０， Ｎｏ．１, 2009, ｐ．４６２-４６９
JPN6015007006; Ｍｏｌｅｃｕｌａｒ Ｖｉｓｉｏｎ Ｖｏｌ．１３, 2007, ｐ．４４３-４５６
JPN6015007009; Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．１１８， Ｎｏ．６, 2008, ｐ．２３３７-２３４６
JPN5008019060; ＳＯＲＢＥＲＡ Ｌ Ａ: ＤＲＵＧＳ ＯＦ ＴＨＥ ＦＵＴＵＲＥ Ｖ２８ Ｎ６, 20030601, Ｐ５４１-５４５
JPN6015007003; Ｉｎｖｅｓｔｉｇａｔｉｖｅ Ｏｐｈｔａｌｍｏｌｏｇｙ ａｎｄ Ｖｉｓｕａｌ Ｓｃｉｅｎｃｅ Ｖｏｌ．５０， Ｎｏ．１, 2009, ｐ．４６２-４６９
JPN6015007006; Ｍｏｌｅｃｕｌａｒ Ｖｉｓｉｏｎ Ｖｏｌ．１３, 2007, ｐ．４４３-４５６
JPN6015007009; Ｔｈｅ Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｉｎｖｅｓｔｉｇａｔｉｏｎ Ｖｏｌ．１１８， Ｎｏ．６, 2008, ｐ．２３３７-２３４６
JPN5008019060; ＳＯＲＢＥＲＡ Ｌ Ａ: ＤＲＵＧＳ ＯＦ ＴＨＥ ＦＵＴＵＲＥ Ｖ２８ Ｎ６, 20030601, Ｐ５４１-５４５
Attorney, Agent or Firm:
Yoshiyuki Inaba
Toshifumi Onuki
Toshifumi Onuki